Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 10, 2025

Hep-G2/2.2.15

RRID:CVCL_L855
Type: Cell Line

Proper Citation

(RRID:CVCL_L855)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_L855

Proper Citation: (RRID:CVCL_L855)

Sex: Male

Defining Citation: PMID:3029758, PMID:8224613, PMID:21448419, PMID:29481805

Comments: Virology: Contains 2 head to tails stably integrated hepatitis B virus (HBV) of the D-genotype., Population: Caucasian.

Category: Cancer cell line

Name: Hep-G2/2.2.15

Synonyms: HEP-G2/2.2.15, Hep-G2/2215, HepG2/2215, HepG2-2.2.15, HepG2 2.2.15, HepG2.2.15, HepG2(2.2.15), 2.2.15

Cross References: BTO:BTO_0005621, CLO:CLO_0001176, CLDB:cl33, cancercelllines:CVCL_L855, ChEMBL-Cells:CHEMBL3833241, ChEMBL-Targets:CHEMBL4296438, CCTCC:GDC0141, Cosmic:979733, Millipore:SCC249, PubChem_Cell_line:CVCL_L855, Wikidata:Q54882787

ID: CVCL_L855

Record Creation Time: 20250131T200406+0000

Record Last Update: 20250131T201626+0000

Ratings and Alerts

No rating or validation information has been found for Hep-G2/2.2.15.

No alerts have been found for Hep-G2/2.2.15.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 537 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Deng R, et al. (2024) ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/?-catenin/PD-L1 axis. iScience, 27(4), 109533.

Wang Y, et al. (2023) HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression. Cancer research, 83(7), 1048.

Smiriglia A, et al. (2023) Sex difference in liver diseases: How preclinical models help to dissect the sex-related mechanisms sustaining NAFLD and hepatocellular carcinoma. iScience, 26(12), 108363.

Zhang B, et al. (2023) An HBV susceptibility variant of KNG1 modulates the therapeutic effects of interferons ? and ?1 in HBV infection by promoting MAVS lysosomal degradation. EBioMedicine, 94, 104694.

Ye Z, et al. (2023) Synthesis and biological evaluation of esculetin derivatives as potential anti-HBV agents. Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 32(5), 899.

Lam MSY, et al. (2023) G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma. Nature communications, 14(1), 563.

Shi Y, et al. (2023) Release of hepatitis B virions is positively regulated by glucose-regulated protein 78 through direct interaction with preS1. Journal of medical virology, 95(1), e28271.

Lee YC, et al. (2023) Development of anti-aflatoxin B1 nanobodies from a novel mutagenesis-derived synthetic library for traditional Chinese medicine and foods safety testing. Journal of biological engineering, 17(1), 30.

Qin YF, et al. (2023) Hepatitis B Virus Surface Antigen Promotes Stemness of Hepatocellular Carcinoma through Regulating MicroRNA-203a. Journal of clinical and translational

hepatology, 11(1), 118.

Kwon H, et al. (2023) Peptidyl-prolyl cis/trans isomerase Pin1 interacts with hepatitis B virus core particle, but not with HBc protein, to promote HBV replication. Frontiers in cellular and infection microbiology, 13, 1195063.

Cao X, et al. (2023) Exploring the mechanism of JiGuCao capsule formula on treating hepatitis B virus infection via network pharmacology analysis and in vivo/vitro experiment verification. Frontiers in pharmacology, 14, 1159094.

Doan PTB, et al. (2023) Super-Resolution Microscopy Analysis of Hepatitis B Viral cccDNA and Host Factors. Viruses, 15(5).

Han Y, et al. (2023) BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma. Clinical and translational medicine, 13(5), e1247.

Liu Y, et al. (2023) Apolipoprotein H induces sex-specific steatohepatitis and gut dysbiosis during chronic hepatitis B infection. iScience, 26(3), 106100.

Li A, et al. (2023) Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma. Frontiers in immunology, 14, 1164448.

Li S, et al. (2023) A systematic study on the treatment of hepatitis B-related hepatocellular carcinoma with drugs based on bioinformatics and key target reverse network pharmacology and experimental verification. Infectious agents and cancer, 18(1), 41.

Yuan S, et al. (2023) HBV X Protein Induces Degradation of UBXN7, a Novel Negative Regulator of NF-?B Signaling, to Promote HBV Replication. Cellular and molecular gastroenterology and hepatology, 15(1), 179.

Xu C, et al. (2023) Sex Differences in Genomic Features of Hepatitis B-Associated Hepatocellular Carcinoma With Distinct Antitumor Immunity. Cellular and molecular gastroenterology and hepatology, 15(2), 327.

Liu L, et al. (2023) HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via SRSF2-Mediated Abnormal PCLAF Splicing. International journal of molecular sciences, 24(4).

Liu X, et al. (2023) ATOH8 promotes HBV immune tolerance by inhibiting the pyroptotic pathway in hepatocytes. Molecular medicine reports, 28(1).